All In Biotech

Drug Trial Radar · NCT05667974

A Study to Evaluate a PIKA Rabies Vaccine(Vero Cell)for Human Use,Freeze-dried

A Phase III, Randomized, Comparator-Controlled, Double-Blind, Multicenter Study to Evaluate the Immunogenicity, Safety and Lot to Lot Consistency of Three Lots of a PIKA Rabies Vaccine(Vero Cell)for Human Use,Freeze-dried in Healthy Adults Using a Post-Exposure Prophylaxis Schedule

Last checked: Nov 20, 2026Latest source record: Jul 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 4,500 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

4,500

Actual

Start

Sep 22, 2023

Primary completion

Mar 22, 2024

Study completion Feb 21, 2025

Sponsor

Sponsor type
Industry
First posted
Dec 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase III, randomized, comparator-controlled, double-blind, multicenter study to evaluate lot-to-lot consistency of three lots of a PIKA Rabies Vaccine, immunogenicity and safety in healthy adults using a post-exposure prophylaxis schedule. It is also the aim of this study to evaluate non-inferiority and superiority of the PIKA Rabies Vaccine compared to the rabies vaccine comparator ChiroRab.

Conditions

  • Rabies
  • Prevention

Interventions

  • PIKA Rabies Vaccine (Vero Cell) for Human use, Freeze-driedBiological

    PIKA rabies vaccine

  • ChirorabBiological

    Active Comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary ImmunogenicityTime frame: 14 days post-vaccination
  2. Primary ImmunogenicityTime frame: 14 days post-vaccination
  3. Co-primary Safety(solicited AEs)Time frame: 7 days after each vaccination.
  4. Co-primary Safety(unsolicited AEs)Time frame: From day of first vaccination through 14 days after the last vaccination
  5. Co-primary Safety(SAEs)Time frame: through study completion, an average of 1 year
  6. Co-primary SafetyTime frame: through study completion, an average of 1 year

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • Al-Shifa Trust Eye Hospital

    Islamabad, Pakistan

  • Ziauddin University

    Karachi, Pakistan

  • Central Park Teaching Hospital

    Lahore, Pakistan

  • TDF-Lakeview,Muntinlupa

    City of Muntinlupa, Philippines

  • Las Pinas Doctor's Hospital

    Las Piñas, Philippines

  • PGH

    Manila, Philippines

  • TDF - San Pablo, Laguna

    San Pablo, Philippines

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.